Lyell Immunopharma Announces 1-for-20 Reverse Stock Split Effective May 30, 2025
Lyell Immunopharma Inc. announced a reverse stock split at a ratio of 1-for-20, effective May 30, 2025. This move will consolidate every 20 shares of the company's common stock into one share, without altering the par value per share. The company's stock will trade on a split-adjusted basis on the Nasdaq Global Select Market starting June 2, 2025, under the new CUSIP number 55083R203. Following the split, the number of outstanding shares will reduce from approximately 296 million to around 14.8 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-129448), on May 28, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。